Free Trial

Capricor Therapeutics (CAPR) Stock Price, News & Analysis

Capricor Therapeutics logo
$7.68 -3.72 (-32.65%)
Closing price 03:58 PM Eastern
Extended Trading
$7.65 -0.03 (-0.42%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Capricor Therapeutics Stock (NASDAQ:CAPR)

Key Stats

Today's Range
$6.74
$8.68
50-Day Range
$6.35
$14.23
52-Week Range
$3.52
$23.40
Volume
19.34 million shs
Average Volume
2.06 million shs
Market Capitalization
$350.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.33
Consensus Rating
Buy

Company Overview

Capricor Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

CAPR MarketRank™: 

Capricor Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 336th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Capricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Capricor Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Capricor Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.75) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Capricor Therapeutics is -5.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Capricor Therapeutics is -5.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Capricor Therapeutics has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Capricor Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    27.32% of the float of Capricor Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Capricor Therapeutics has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Capricor Therapeutics has recently increased by 9.40%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Capricor Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Capricor Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    27.32% of the float of Capricor Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Capricor Therapeutics has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Capricor Therapeutics has recently increased by 9.40%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Capricor Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Capricor Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    2 people have searched for CAPR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.50% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 21.68% of the stock of Capricor Therapeutics is held by institutions.

  • Read more about Capricor Therapeutics' insider trading history.
Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAPR Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

CAPR Stock Analysis - Frequently Asked Questions

Capricor Therapeutics' stock was trading at $13.80 on January 1st, 2025. Since then, CAPR shares have decreased by 45.1% and is now trading at $7.5740.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) issued its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.20. The biotechnology company had revenue of $2.73 million for the quarter, compared to analysts' expectations of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative trailing twelve-month return on equity of 62.42%.
Read the conference call transcript
.

Capricor Therapeutics' top institutional investors include Krilogy Financial LLC (0.09%). Insiders that own company stock include Shinyaku Co Ltd Nippon, David B Musket, Paul Gisbert Auwaerter and Xavier Avat.
View institutional ownership trends
.

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/13/2025
Today
7/11/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CAPR
CIK
1133869
Employees
101
Year Founded
N/A

Price Target and Rating

High Price Target
$77.00
Low Price Target
$20.00
Potential Upside/Downside
+313.7%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.47 million
Net Margins
-181.71%
Pretax Margin
-317.12%
Return on Equity
-62.42%
Return on Assets
-48.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.55
Quick Ratio
6.55

Sales & Book Value

Annual Sales
$22.27 million
Price / Sales
15.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.20 per share
Price / Book
2.43

Miscellaneous

Outstanding Shares
45,680,000
Free Float
40,881,000
Market Cap
$355.76 million
Optionable
Optionable
Beta
0.82

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CAPR) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners